8 results
10-K
2023 FY
FTRE
Fortrea Holdings Inc
13 Mar 24
Annual report
4:39pm
for innovative biotechnology companies. We believe our customer base positions us at the forefront of innovation in healthcare and allows us to help our … and by utilizing innovative solutions to support the diversity plans expected by global regulatory authorities, we will further strengthen our reputation
8-K
EX-99.2
FTRE
Fortrea Holdings Inc
11 Mar 24
Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
6:35am
a proud, decades-long track record of market leadership in supporting clinical research and commercialization of innovative therapies. Arsenal takes
8-K
EX-99.1
FTRE
Fortrea Holdings Inc
11 Mar 24
Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
6:35am
and employees have responded favorably to our patient-inspired purpose and our innovative solutions, combining leading science, technology and people
8-K
EX-99.1
FTRE
Fortrea Holdings Inc
3 Jul 23
Entry into a Material Definitive Agreement
4:05pm
expertise
with innovative solutions that provide access to unique clinical data assets. Our relationship with Labcorp and other leading third parties … leading pharmaceuticals customers and innovative biotechnology companies. In 2022, 54% of our revenue came from leading pharmaceutical customers. We
10-12B/A
EX-99.1
FTRE
Fortrea Holdings Inc
8 Jun 23
Registration of securities (amended)
10:33am
for adaptable engagements with large and small customers. We intend to differentiate this pairing of technical expertise
with innovative solutions … and innovative biotechnology companies. In 2022, 54% of our revenue came from leading pharmaceutical customers. We believe our customer base positions us
10-12B/A
EX-99.1
tjzifk
2 Jun 23
Registration of securities (amended)
5:07pm
10-12B
EX-99.1
s0sd07rs1e
15 May 23
Registration of securities
3:20pm
DRS/A
EX-99.1
bcxrsuaj8
5 Apr 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next